The FDA is reviewing supplemental biologics license applications for guselkumab to treat children with juvenile psoriatic arthritis and moderate to severe plaque psoriasis.
For the 2024 Image Competition, the ACR sought images with educational or remarkable manifestations representing a diverse range of pediatric patients with autoimmune, inflammatory, infectious and malignant drivers of rheumatic disease. Here, we showcase the winning images from Latin America and the Caribbean. Diagnosing Juvenile PsA A 13-year-old boy presented with a seven-year history of…
Maternal Health Insights in Patients with SLE The impact of pregnancy readiness on lupus activity, maternal mental health & pregnancy outcomes By Ceshae Harding, MD, & Megan Clowse, MD, MPH Why was this study done? Patients with systemic lupus erythematosus (SLE) who are pregnant have increased risks of risks maternal and fetal mortality, preeclampsia and…
Sendaydiego et al. asked: Do some DMARDs pose a greater cancer risk than others for patients with RA? Here are insights from the study and its clinical implications.
FDA has granted Descartes-08, an mRNA chimeric antigen receptor T cell therapy, a rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Reproductive health, biosimilars, IgG4-related disease and much more—five speakers give us a sneak peek into important topics being addressed at the ACR’s 2025 State-of-the-Art Clinical Symposium, April 4–6.
Pulmonary hypertension and Raynaud’s phenomenon are just some of the symptoms patients with systemic sclerosis (SSc) may experience. Here are insights into the diagnosis and management of SSc.
In individuals without radiographic knee osteoarthritis (OA), Chang et al. investigated whether magnetic resonance imaging (MRI) defined knee OA at baseline was associated with incident radiographic and symptomatic disease during up to 11 years of follow-up. The researchers found the two current MRI definitions of knee OA may not adequately predict the development of radiographic and symptomatic disease.
Daniel H. Solomon, MD, MPH, & Andrew Concoff, MD, FACR |
Over our 25 years as rheumatologists, care has advanced greatly. We each completed our rheumatology training in the late 1990s when both infliximab and etanercept first arrived on the U.S. market, ushering in the era of biologics in rheumatology. Since this time, our greater understanding of the immunologic basis of many rheumatic diseases has translated…
Lisa Christopher-Stine, MD, MPH, discussed the latest findings on myositis and its subtypes, including insights into antibodies linked to cancer and treatments for these patients.